Old Web
English
Sign In
Acemap
>
Paper
>
PRS32 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Type 2 Severe Asthma in Italy
PRS32 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Type 2 Severe Asthma in Italy
2020
M.P. Pedone
F. Fanelli
A. Serra
Rossella Bitonti
Gianluca Furneri
Keywords:
severe asthma
Dupilumab
Intensive care medicine
Cost-effectiveness analysis
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]